Cost‐effectiveness of first‐line immunotherapies for advanced non‐small cell lung cancer

Yang, Sheng‐An; Ou, Horng Yih; Su, Wu‐Chou; Wang, Shi Yi

doi:10.1002/cam4.5632

Cited by 4 publications

(1 citation statement)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar findings were also revealed in a meta-analysis enrolling 19 phase II/III RCTs in which the ABCP regimen was ranked 5 th among all 17 regimens including ABCP, 5 ICI-monotherapy regimens, 7 ICI-Chemo regimens, 2 dual-ICI strategies, 1 dual-ICI-Chemo combination, and 1 Beva-Chemo regimen, in which overall OS, PFS, safety, and ORR were taken into consideration ( 69 ). Furthermore, a cost-effectiveness analysis from the perspective of the US health care sector showed that adopting pembrolizumab monotherapy when PD-L1≥50%, pembrolizumab combined with chemotherapy when PD-L1 between 1%-49%, and nivolumab plus ipilimumab when PD-L1<1% were more cost-effective treatment options, whose performance was better than ABCP (QALY 2.39) ( 70 ). Similar results were revealed in several other cost-effectiveness analyses ( 71 ).…”

Section: Clinical Practices Of Anti-pd-1/pd-l1 Antibodies Plus Antian...mentioning

confidence: 99%

Research advances in mechanism of antiangiogenic therapy combined with immune checkpoint inhibitors for treatment of non-small cell lung cancer

He,

Wang,

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

Immunotherapy has changed the treatment strategy of non-small cell lung cancer (NSCLC) in recent years, among which anti-PD-1/PD-L1 antibodies are the most used. However, the majority of patients with NSCLC do not derive benefit from immune checkpoint inhibitors (ICIs). Vascular abnormalities are a hallmark of most solid tumors and facilitate immune evasion. Thus, combining antiangiogenic therapies might increase the effectiveness of anti-PD-1/PD-L1 antibodies. In this paper, the mechanisms of anti-angiogenic agents combined with anti-PD-1/PD-L1 antibodies are illustrated, moreover, relevant clinical studies and predictive immunotherapeutic biomarkers are summarized and analyzed, in order to provide more treatment options for NSCLC patients.

show abstract

Section: Clinical Practices Of Anti-pd-1/pd-l1 Antibodies Plus Antian...mentioning

confidence: 99%

Research advances in mechanism of antiangiogenic therapy combined with immune checkpoint inhibitors for treatment of non-small cell lung cancer

He,

Wang,

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

show abstract

Cost‐effectiveness of first‐line immunotherapies for advanced non‐small cell lung cancer

Yang

et al. 2023

Cancer Medicine

Self Cite

View full text Add to dashboard Cite

show abstract

First-line treatments for advanced non-squamous non-small cell lung cancer with immune checkpoint inhibitors plus chemotherapy: a systematic review, network meta-analysis, and cost-effectiveness analysis

Tian,

Niu,

Shi

et al. 2024

Ther Adv Med Oncol

View full text Add to dashboard Cite

Introduction: The combination of immune checkpoint inhibitors (ICIs) and chemotherapy is a promising first-line therapy for patients with advanced non-squamous non-small cell lung cancer (NSCLC). The cost-effectiveness of combinations with different ICIs is yet to be compared. Methods: We utilized Bayesian network meta-analyses for the comparisons of overall survival, progression-free survival, and incidence of adverse events of the included treatments in the total population and subgroups with different programmed death-ligand 1 tumor proportional scores (TPS). The cost-effectiveness of the treatments from the perspectives of the US and Chinese healthcare systems was assessed using Markov models. Results: Three combinations, including pembrolizumab + chemotherapy (PembroC), nivolumab + ipilimumab + chemotherapy (NivoIpiC), and atezolizumab + chemotherapy (AteC), were included in our study. In terms of efficacy, PembroC was most likely to be ranked first for extending progression-free survival (PFS) (93.16%) and overall survival (OS) (90.73%). Nevertheless, from the US perspective, NivoIpiC and PembroC showed incremental cost-effectiveness ratios (ICERs) of $68,963.1/quality-adjusted life-years (QALY) and $179,355.6/QALY, respectively, compared with AteC. The one-way sensitivity analysis revealed that the results were primarily sensitive to the hazard ratios for OS or the cost of immunotherapy agents. At a willingness-to-pay (WTP) threshold of $150,000/QALY, NivoIpiC had the highest probability of being cost-effective (63%). As for the Chinese perspective, NivoIpiC and PembroC had ICERs of $145,983.4/QALY and $195,863.3/QALY versus AteC, respectively. The results were primarily sensitive to the HRs for OS. At a WTP threshold of $38,017/QALY, AteC had the highest probability of cost-effectiveness (94%). Conclusion: Although PembroC has the optimal efficacy, NivoIpiC and AteC were the most favorable treatments in terms of cost-effectiveness for patients with advanced non-squamous NSCLC from the US and Chinese perspectives, respectively.

show abstract

Cost‐effectiveness of first‐line immunotherapies for advanced non‐small cell lung cancer

Abstract: This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Cited by 4 publications

References 49 publications

Research advances in mechanism of antiangiogenic therapy combined with immune checkpoint inhibitors for treatment of non-small cell lung cancer

Research advances in mechanism of antiangiogenic therapy combined with immune checkpoint inhibitors for treatment of non-small cell lung cancer

Cost‐effectiveness of first‐line immunotherapies for advanced non‐small cell lung cancer

First-line treatments for advanced non-squamous non-small cell lung cancer with immune checkpoint inhibitors plus chemotherapy: a systematic review, network meta-analysis, and cost-effectiveness analysis

Contact Info

Product

Resources

About